NCT04280536View on ClinicalTrials.gov

Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

Cohort A

Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.

DRUG

Cohort B

Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER